undamentalytics Newsletter

Genedx Holdings Corp. insider trading

Every open-market purchase and sale by Genedx Holdings Corp.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Genedx Holdings Corp. insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Genedx Holdings Corp.’s insiders pay?

From November 2, 2021 to September 18, 2026, 22 insiders reported 25 open-market purchases and 123 sales not made under a pre-set plan in Genedx Holdings Corp. Twelve months after each purchase was reported, the shares were +217.3% against the S&P 500 on average (median +168.7%), over 8 purchases with a full year of prices; 75% beat the index. After sales, the shares moved +113.1% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 23, 2023 into $84,775 by November 2, 2026, +86.5% a year. It held shares 100% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $19,080 (+20.7% a year), and held throughout $19,080 (+20.7%).

$0$100k$200k 2023202420252026 $84.8k$19.1k$19.1k
Copying Genedx Holdings Corp.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Genedx Holdings Corp.'s insiders from May 23, 2023, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 100% of the time.
Genedx Holdings Corp.: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Feeley Kevin CHIEF FINANCIAL OFFICER 0 — — 43 +87.7% (24) September 18, 2026
Stueland Katherine CHIEF EXECUTIVE OFFICER 1 — — 41 +149.3% (24) September 18, 2026
Opko Health, Inc. 10% owner 1 — — 9 +203.3% (9) August 19, 2024
Meister Keith A. Director 5 −65.2% (1) 0% 2 — May 15, 2026
Casdin Eli Director 5 +222.5% (2) 100% 1 −46.5% (1) June 8, 2026
Ro Isaac Chief Financial Officer 0 — — 6 −76.0% (3) August 10, 2022
Saad Kareem CHIEF TRANSFORMATION OFFICER 0 — — 5 +515.3% (2) March 19, 2024
Ryan Jason Executive Chairman 1 — — 3 +20.6% (2) August 27, 2025
Schadt Eric President & Chief R&D Officer 1 — — 3 −70.3% (1) May 24, 2022
Icahn School Of Medicine At Mount Sinai 10% owner 1 — — 2 +93.2% (2) November 19, 2024
Pfenniger Richard C Jr Director 3 +132.0% (1) 100% 0 — November 8, 2023
Assad Shawn Chief Accounting Officer 0 — — 2 −75.3% (1) February 14, 2022
Casdin Capital, LLC Director 2 +168.7% (2) 100% 0 — June 5, 2024
Casdin Partners Master Fund, L.P. Director 2 +952.4% (1) 100% 0 — May 20, 2026
White Karen Ann Chief People Officer 0 — — 2 −70.3% (1) March 13, 2023
Btoa L.L.C. and related entities 10% owner 1 — — 0 — May 3, 2022
Coffin James President and COO 0 — — 1 −70.3% (1) November 2, 2021
Corvex Management LP Director 1 −63.1% (1) 0% 0 — May 16, 2025
Dechairo Bryan Chief Operating Officer 0 — — 1 — February 3, 2026
Mount Sinai Health System, Inc. 10% owner 1 — — 0 — February 2, 2023
Prentice Anthony Chief Product Officer 0 — — 1 −70.3% (1) November 2, 2021
Ruch Joshua Director 0 — — 1 — November 26, 2025

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Genedx Holdings Corp.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Genedx Holdings Corp. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 4 selling crowds, +92.1%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
June 30, 20263 buying+7.8%not yetnot yet
August 29, 20254 selling+22.7%−46.6%−53.9%
July 31, 20243 selling+150.8%+118.8%+215.1%
March 28, 20243 selling+181.9%+358.7%+817.9%
November 30, 20217 selling−47.7%−62.6%−84.6%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Genedx Holdings Corp. · Funds · Politicians